Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00686712 · ClinicalTrials.gov registry record · Phase 4
Insulin Glargine at Bedtime or in AM Versus NPH
A Phase 4 study, sponsored by Charles Drew University of Medicine and Science.
- Completed
- Registry status
- Phase 4
- Development phase
- 108
- Enrollment target
NCT00686712: Completed Phase 4 study, sponsored by Charles Drew University of Medicine and Science.
NCT00686712 is a Phase 4 study that has completed, run by Charles Drew University of Medicine and Science. The registered enrollment target is 108 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (79% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00686712, a Phase 4 study, has completed, sponsored by Charles Drew University of Medicine and Science.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 108 participants
- Enrollment target
Study Summary
To compare the efficacy and safety of once-nightly insulin glargine versus a single morning injection of glargine or once-nightly NPH insulin in ethnic minority type 2 diabetic patients inadequately controlled on combination oral agents.
Interventions
- DRUG 1- Insulin glargine QHS
- DRUG 2 - Insulin glargine QAM
- DRUG 3 - NPH insulin QHS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2003-02 |
| Est. Completion | 2009-08 |
| Phase | Phase 4 |
What the finished NCT00686712 record still lists
NCT00686712 is an interventional study that assigns participants to a tested intervention. The registered 108 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (79% lower).
The record links to 0 conditions, and to 3 interventions - of which 1- Insulin glargine QHS is the first listed.
NCT00686712 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00686712 about?
NCT00686712 is a clinical study titled "Insulin Glargine at Bedtime or in AM Versus NPH". To compare the efficacy and safety of once-nightly insulin glargine versus a single morning injection of glargine or once-nightly NPH insulin in ethnic minority type 2 diabetic patients inadequately controlled on combination oral agents.
What is the current status of trial NCT00686712?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 108 participants. The study started on 2003-02. Estimated completion is 2009-08.
What interventions are being tested in trial NCT00686712?
The interventions under investigation include: 1- Insulin glargine QHS (DRUG), 2 - Insulin glargine QAM (DRUG), 3 - NPH insulin QHS (DRUG).
Who is sponsoring clinical trial NCT00686712?
This trial is sponsored by Charles Drew University of Medicine and Science, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00686712's enrollment target sits among peer trials
108 740th of 2000 higher than 1,256 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02703207 · 108 participants · NA
Neurocognitive and Health Impact of Sleep Apnea in Elderly Veterans With Comorbid COPD
- NCT02744677 · 108 participants · NA
COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction
- NCT02781883 · 108 participants · Phase 2
Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML
- NCT03848663 · 108 participants · NA
Visual Remapping to Aid Reading With Field Loss
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia